Compare TYRA & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | HURN |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2021 | 2004 |
| Metric | TYRA | HURN |
|---|---|---|
| Price | $25.94 | $110.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $47.50 | ★ $204.40 |
| AVG Volume (30 Days) | ★ 732.5K | 225.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | N/A | ★ $1,699,143,000.00 |
| Revenue This Year | N/A | $11.80 |
| Revenue Next Year | N/A | $8.23 |
| P/E Ratio | ★ N/A | $81.83 |
| Revenue Growth | N/A | ★ 11.65 |
| 52 Week Low | $8.98 | $100.10 |
| 52 Week High | $40.65 | $186.78 |
| Indicator | TYRA | HURN |
|---|---|---|
| Relative Strength Index (RSI) | 26.61 | 48.13 |
| Support Level | $24.88 | $100.80 |
| Resistance Level | $31.57 | $135.59 |
| Average True Range (ATR) | 1.84 | 4.35 |
| MACD | -0.68 | 1.25 |
| Stochastic Oscillator | 7.40 | 87.24 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.